1. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2012 (updated). http://www.ginasthma.org/local/uploads/files/GINA_Report_2012Feb13.pdf (Accessed 3 Apr 2013).
2. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Resp J. 2003;22(3):470–7.
3. European Medicines Agency. Xolair powder and solvent for solution for injection: summary of product characteristics; 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf (Accessed 3 Jun 2013).
4. Plosker GL, Keam SJ. Omalizumab: a review of its use in the treatment of allergic asthma. BioDrugs. 2008;22(3):189–204.
5. Soresi S, Togias A. Mechanisms of action of anti-immunoglobulin E therapy. Allergy Asthma Proc. 2006;27(2 Suppl. 1):S15–23.